Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2005

Open Access 01-12-2005 | Research

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration

Authors: Soni Pullamsetti, Stefanie Krick, Hüseyin Yilmaz, Ardeschir Hossein Ghofrani, Christian Schudt, Norbert Weissmann, Beate Fuchs, Werner Seeger, Friedrich Grimminger, Ralph Theo Schermuly

Published in: Respiratory Research | Issue 1/2005

Login to get access

Abstract

Background

The aim of the study was to assess the chronic effects of combined phosphodiesterase 3/4 inhibitor tolafentrine, administered by inhalation, during monocrotaline-induced pulmonary arterial hypertension (PAH) in rats.

Methods

CD rats were given a single subcutaneous injection of monocrotaline to induce PAH. Four weeks after, rats were subjected to inhalation of tolafentrine or sham nebulization in an unrestrained, whole body aerosol exposure system. In these animals (i) the acute pulmonary vasodilatory efficacy of inhaled tolafentrine (ii) the anti-remodeling effect of long-term inhalation of tolafentrine (iii) the effects of tolafentrine on the expression profile of 96 genes encoding cell adhesion and extracellular matrix regulation were examined. In addition, the inhibitory effect of tolafentrine on ex vivo isolated pulmonary artery SMC cell migration was also investigated.

Results

Monocrotaline injection provoked severe PAH (right ventricular systolic pressure increased from 25.9 ± 4.0 to 68.9 ± 3.2 after 4 weeks and 74.9 ± 5.1 mmHg after 6 weeks), cardiac output depression and right heart hypertrophy. The media thickness of the pulmonary arteries and the proportion of muscularization of small precapillary resistance vessels increased dramatically, and the migratory response of ex-vivo isolated pulmonary artery smooth muscle cells (PASMC) was increased. Micro-arrays and subsequent confirmation with real time PCR demonstrated upregulation of several extracellular matrix regulation and adhesion genes, such as matrixmetalloproteases (MMP) 2, 8, 9, 10, 11, 12, 20, Icam, Itgax, Plat and serpinb2. When chronically nebulized from day 28 to 42 (12 daily aerosol maneuvers), after full establishment of severe pulmonary hypertension, tolafentrine reversed about 60% of all hemodynamic abnormalities, right heart hypertrophy and monocrotaline-induced structural lung vascular changes, including the proportion of pulmonary artery muscularization. The upregulation of extracellular matrix regulation and adhesion genes was reduced by nearly 80% by inhalation of the tolafentrine. When assessed in vitro, tolafentrine blocked the enhanced PASMC migratory response.

Conclusion

In conclusion, we demonstrate for the first time that inhalation of combined PDE3/4 inhibitor reverses pulmonary hypertension fully developed in response to monocrotaline in rats. This "reverse-remodeling" effect includes structural changes in the lung vascular wall and key molecular pathways of matrix regulation, concomitant with 60% normalization of hemodynamics.
Literature
1.
D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343–349.CrossRefPubMed
2.
Archer S, Rich S: Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 2000, 102:2781–2791.CrossRefPubMed
3.
Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994, 75:539–545.CrossRefPubMed
4.
Strauss BH, Robinson R, Batchelor WB, Chisholm RJ, Ravi G, Natarajan MK, Logan RA, Mehta SR, Levy DE, Ezrin AM, Keeley FW: In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res 1996, 79:541–550.CrossRefPubMed
5.
Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf A, Adnot S, Dortho MP: Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J 2001, 18:838–845.CrossRefPubMed
6.
Qin Y, Zhou A, Ben X, Shen J, Liang Y, Li F: All-trans retinoic acid in pulmonary vascular structural remodeling in rats with pulmonary hypertension induced by monocrotaline. Chin Med J (Engl) 2001, 114:462–465.
7.
Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M: Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000, 6:698–702.CrossRefPubMed
8.
Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M: Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 2002, 105:516–521.CrossRefPubMed
9.
Giannelli G, Iannone F, Marinosci F, Lapadula G, Antonaci S: The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin 2005, 21:327–332.CrossRefPubMed
10.
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004, 169:39–45.CrossRefPubMed
11.
Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schudt C, Ermert L, Seeger W, Grimminger F: Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004, 94:1101–1108.CrossRefPubMed
12.
Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725–748.PubMed
13.
Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E: Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995, 322:1–13.CrossRefPubMed
14.
Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.CrossRefPubMed
15.
Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.CrossRefPubMed
16.
Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D: Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000, 292:512–520.PubMed
17.
Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D, Ghofrani HA: Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001, 164:1694–1700.CrossRefPubMed
18.
Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med 2002, 30:2489–2492.CrossRefPubMed
19.
Huxtable RJ: Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 1990, 47:371–389.CrossRefPubMed
20.
Rosenberg HC, Rabinovitch M: Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988, 255:H1484-H1491.PubMed
21.
Kato S, Sugimura H, Kishiro I, Machida M, Suzuki H, Kaneko N: Suppressive effect of pulmonary hypertension and leukocyte activation by inhaled prostaglandin E1 in rats with monocrotaline-induced pulmonary hypertension. Exp Lung Res 2002, 28:265–273.CrossRefPubMed
22.
Nagaya N, Okumura H, Uematsu M, Shimizu W, Ono F, Shirai M, Mori H, Miyatake K, Kangawa K: Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 2003, 285:H2125-H2131.CrossRefPubMed
23.
Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W: Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. Am J Respir Crit Care Med 2005, 172:358–363.CrossRefPubMed
24.
Schermuly R, Schmehl T, Gunther A, Grimminger F, Seeger W, Walmrath D: Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury. Impact on gas exchange. Am J Respir Crit Care Med 1997, 156:445–453.CrossRefPubMed
25.
Schermuly RT, Ghofrani HA, Enke B, Weissmann N, Grimminger F, Seeger W, Schudt C, Walmrath D: Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:1500–1506.CrossRefPubMed
26.
Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998, 4:1329–1333.CrossRefPubMed
27.
Irani C, Goncharova EA, Hunter DS, Walker CL, Panettieri RA, Krymskaya VP: Phosphatidylinositol 3-kinase but not tuberin is required for PDGF-induced cell migration. Am J Physiol Lung Cell Mol Physiol 2002, 282:L854-L862.CrossRefPubMed
28.
Olschewski H, Olschewski A, Rose F, Schermuly R, Schutte H, Weissmann N, Seeger W, Grimminger F: Physiologic basis for the treatment of pulmonary hypertension. J Lab Clin Med 2001, 138:287–297.CrossRefPubMed
29.
Olschewski H, Rose F, Grunig E, Ghofrani HA, Walmrath D, Schulz R, Schermuly R, Grimminger F, Seeger W: Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 2001, 138:367–377.CrossRefPubMed
30.
Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW: Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000, 102:3130–3136.CrossRefPubMed
31.
Phillips PG, Long L, Wilkins MR, Morrell NW: cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005, 288:L103-L115.CrossRefPubMed
32.
Hsieh CC, Lau Y: Migration of vascular smooth muscle cells is enhanced in cultures derived from spontaneously hypertensive rat. Pflugers Arch 1998, 435:286–292.CrossRefPubMed
33.
Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG: Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994, 75:41–54.CrossRefPubMed
34.
Johnson JL, van Eys GJ, Angelini GD, George SJ: Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 2001, 21:1146–1151.CrossRefPubMed
35.
Yang GY, Yao JS, Huey M, Hashimoto T, Young WL: Participation of PI3K and ERK1/2 pathways are required for human brain vascular smooth muscle cell migration. Neurochem Int 2004, 44:441–446.CrossRefPubMed
36.
Horio T, Kohno M, Kano H, Ikeda M, Yasunari K, Yokokawa K, Minami M, Takeda T: Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res 1995, 77:660–664.CrossRefPubMed
37.
Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG: Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A 1993, 90:10300–10304.CrossRefPubMedPubMedCentral
38.
Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R: Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994, 93:1266–1274.CrossRefPubMedPubMedCentral
39.
Rabinovitch M: Investigational approaches to pulmonary hypertension. Toxicol Pathol 1991, 19:458–469.CrossRefPubMed
40.
Tozzi CA, Poiani GJ, Harangozo AM, Boyd CD, Riley DJ: Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest 1989, 84:1005–1012.CrossRefPubMedPubMedCentral
41.
McCawley LJ, Li S, Benavidez M, Halbleib J, Wattenberg EV, Hudson LG: Elevation of intracellular cAMP inhibits growth factor-mediated matrix metalloproteinase-9 induction and keratinocyte migration. Mol Pharmacol 2000, 58:145–151.PubMed
42.
Peracchia F, Tamburro A, Prontera C, Mariani B, Rotilio D: cAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler Thromb Vasc Biol 1997, 17:3185–3190.CrossRefPubMed
43.
Takahashi N, Tetsuka T, Uranishi H, Okamoto T: Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur J Biochem 2002, 269:4559–4565.CrossRefPubMed
44.
Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T: Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 2001, 8:1635–1642.CrossRefPubMed
Metadata
Title
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
Authors
Soni Pullamsetti
Stefanie Krick
Hüseyin Yilmaz
Ardeschir Hossein Ghofrani
Christian Schudt
Norbert Weissmann
Beate Fuchs
Werner Seeger
Friedrich Grimminger
Ralph Theo Schermuly
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2005
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-6-128

Other articles of this Issue 1/2005

Respiratory Research 1/2005 Go to the issue

Research

Fractal ventilation enhances respiratory sinus arrhythmia

Research

The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo

Research

Chronic pneumonia with Pseudomonas aeruginosa and impaired alveolar fluid clearance

Research

Titanium dioxide particle – induced goblet cell hyperplasia : association with mast cells and IL-13

Research

Inhibition of breathing after surfactant depletion is achieved at a higher arterial PCO2 during ventilation with liquid than with gas

Research

Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits